Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Combination shows consistent benefit across prespecified post-progression outcomes
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
